✦ LIBER ✦

Clinical experience with Flebogamma® 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease

✍ Scribed by M. Ballow

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Multicenter, Prospective, Open Label,

✍ Melvin Berger; The Flebogamma® 5% DIF Investigators 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 126 KB

Efficacy and Tolerability of an Argentin

✍ S. Krasovec; A. Ornani; M. Oleastro; S. Rosenzweig; A. Roy; L. Perez; G. Campos; 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 175 KB

Safety and Efficacy of Privigen®, a Nove

✍ Mark R. Stein; Robert P. Nelson; Joseph A. Church; Richard L. Wasserman; Michael 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 166 KB

Efficacy and Safety of a New 20% Immunog

✍ John B. Hagan; Mary B. Fasano; Sheldon Spector; Richard L. Wasserman; Isaac Mela 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 197 KB

Efficacy and Safety of Hizentra®, a New

✍ Michael Borte; Malgorzata Pac; Margit Serban; Teresa Gonzalez-Quevedo; Bodo Grim 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 182 KB

Efficacy, Safety and Tolerability of a N

✍ Joseph A. Church; Heinz Leibl; Mark R. Stein; Isaac R. Melamed; Arye Rubinstein; 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 443 KB